文献速递妇科肿瘤

基于个体发育癌场理论的宫颈癌手术切除:单中心前瞻性观察队列研究的成熟结果

Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study.
PubMed 文献 · Lancet Oncol · 2019-08-02

BACKGROUND: Previous findings from our centre suggest that carcinoma of the cervix propagates within ontogenetic cancer fields, tissue compartments defined by staged morphogenesis.…

要点

  • 治疗相关2级和3级并发症分别为21%和3%。

核心结论

  • 基于个体发育癌场的全或扩大系膜切除加治疗性淋巴结清扫在单中心取得良好生存结局,但需多中心试验进一步验证。

研究设计与样本

  • 单中心、前瞻性、观察性队列研究(Leipzig School Mesometrial Resection Study),最终临床与组织病理学评估。
  • 纳入任何年龄的2009 FIGO IB1、IB2、IIA1、IIA2或IIB期宫颈癌患者,行全系膜切除或扩大系膜切除及治疗性淋巴结清扫。
  • 主要结局为疾病特异性生存、无复发生存及治疗相关并发症(Franco-Italian词汇表评估)。
  • 采用Cox比例风险模型比较个体发育局部(T)和区域(N)肿瘤分期与病理T和N分期。

主要发现

  • 523例按方案治疗患者中,治疗相关并发症包括112例(21%)2级和15例(3%)3级。
  • 最常见中重度治疗相关并发症及后遗症为伤口裂开17例(3%)、肾积水17例(3%)、肠梗阻26例(5%)和淋巴水肿33例(6%)。
  • 1例(<1%)接受全系膜切除的患者死于术后脑梗死。

关键数值与推荐

  • 将前哨淋巴结、一线、二线和三线淋巴结区域定义为进展性区域癌场。
  • 基于个体发育癌场行全系膜切除或扩大系膜切除及治疗性淋巴结清扫,旨在实现局部区域肿瘤控制而无需辅助放疗。

临床怎么用

  • 对于2009 FIGO IB1-IIB期宫颈癌,可考虑基于个体发育癌场的手术切除及治疗性淋巴结清扫作为实现局部区域控制、避免辅助放疗的策略。
  • 该术式在单中心显示良好生存和可接受的并发症谱,但应在多中心试验中进一步验证后方可广泛推广。

局限性

  • 单中心研究,结果需多中心试验进一步验证。
  • 为观察性队列研究,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous findings from our centre suggest that carcinoma of the cervix propagates within ontogenetic cancer fields, tissue compartments defined by staged morphogenesis. We aimed to determine whether surgical treatment that accounts for stage-associated, ontogenetic cancer fields and their associated lymphoid tissues results in locoregional tumour control without the need for adjuvant radiotherapy. METHODS: We did the final clinical and histopathological evaluation of data from, the single-centre, observational, cohort study, the Leipzig School Mesometrial Resection Study. Patients of any age with stage IB1, IB2, IIA1, IIA2, or IIB cervical cancer (according to 2009 International Federation of Gynecology and Obstetrics [FIGO]) had total mesometrial resection or extended mesometrial resection and therapeutic lymph node dissection, done on the basis of ontogenetic cancer fields. We defined sentinel node, first-line, second-line, and third-line lymph node regions as progressive regional cancer fields. Primary outcomes were disease-specific survival and recurrence-free survival, and treatment-related morbidity (assessed with the Franco-Italian glossary). Applying Cox proportional hazard models, ontogenetic local (T) and regional (N) tumour staging was compared with pathological T and N staging. This trial is registered with the German Clinical Trials Register, number DRKS00015171. FINDINGS: Between Oct 16, 1999, and June 27, 2017, 523 patients were treated per protocol and followed up for a median of 61·8 months (IQR 49·3-94·8). In 495 patients with cervical cancer treated with cancer field surgery, 5-year disease-specific survival was 89·4% (95% CI 86·5-92·4) and recurrence-free survival was 83·1% (79·7-86·6). In the per-protocol population of 523 patients, treatment-related morbidity comprised 112 (21%) grade 2 and 15 (3%) grade 3 complications. The most common moderate and severe treatment-related complications and sequelae were wound dehiscence (17 [3%]), hydronephrosis (17 [3%]), bowel obstruction (26 [5%]), and lymph oedema (33 [6%]). One patient (<1%), who received total mesometrial resection, died from postoperative brain infarction. INTERPRETATION: Total or extended mesometrial resection with therapeutic lymph node dissection based on ontogenetic cancer fields results in good survival outcomes of patients with cervical cancer in our institution, but needs to be investigated further in multicentre trials. FUNDING: Leipzig School of Radical Pelvic Surgery, University of Leipzig Medical School, and the Gynecologic Oncology Research Foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Höckel M, Wolf B, Schmidt K, et al. Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study. Lancet Oncol. 2019. PMID: 31383547. doi:10.1016/S1470-2045(19)30389-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。